A downtrend has been apparent in Cyclacel Pharmaceuticals, Inc. (CYCC) lately. While the stock has lost 13.8% over the past week, it could witness a trend reversal as a hammer chart pattern was formed ...
Cyclacel Pharmaceuticals, Inc. (CYCC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...
BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative ...
As of February 6, 2023, the average one-year price target for Cyclacel Pharmaceuticals is $16.58. The forecasts range from a low of $10.10 to a high of $23.10. The average price target represents an ...
Hosted on MSN
Cyclacel Stock Tumbles Over 76% Since Regaining Nasdaq Compliance: What’s Ailing the Nanocap Biopharma Firm?
Cyclacel Pharmaceuticals, Inc. (CYCC) has been in a downward spiral in 2025, with its stock plunging over 94% year-to-date and more than 76% even after it regained Nasdaq compliance earlier this month ...
This week was a good one for a few biotechs, but not so great for others. Two in particular have just put out news relating to trials for their lead investigative assets, and both have taken a hit on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results